Coronavirus Response - Active Support for Hospitalised Covid-19 Patients

• Status: Withdrawn
• Trial end date: 2021-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: London School of Hygiene and Tropical Medicine
• Treatments: Aspirin; Losartan; Simvastatin

Criteria

Inclusion Criteria:

• Adults age 40 years and older

• with suspected or confirmed acute COVID-19 infection. Acute COVID-19 infection is suspected in the presence of a fever and at least one symptom of respiratory disease e.g. cough, difficulty breathing, signs of hypoxia. The clinician may suspect COVID-19 infection if i) the patient lives in or has recently travelled to an area with COVID-19 transmission; ii) the patient had recent contact with a confirmed or probable COVID-19 case, or iii) no alternative diagnosis fully explains the clinical presentation

• requiring hospitalisation

Exclusion Criteria:

• Women known to be pregnant

• Patients hospitalised without symptoms of acute COVID-19 infection should not be recruited even if they test positive for COVID-19

• Patients already receiving mechanical ventilation

• Patients with a definite indication or contraindication for any of the trial treatments.

• Patients who are very severely frail (completely dependent and approaching end of life who typically they could not recover even from a mild illness) or terminally ill should not be recruited.